Dengue Vaccine: The Current Status.

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Dengue fever is a significant and re-emerging global health threat, with a substantial portion of the world's population at risk.
• Current limitations in antiviral treatments and the ineffectiveness of vector control programs highlight the urgent need for vaccination strategies.
• An ideal dengue vaccine must confer long-lasting immunity against all four dengue virus serotypes.

Purpose of the Study:

• To review current dengue vaccine candidates and their developmental stages.
• To assess the potential of various vaccine platforms, including live attenuated, chimeric, and recombinant approaches.
• To identify challenges in achieving a balanced immune response against all dengue serotypes.

Main Methods:

• Review of existing literature on dengue vaccine development.
• Analysis of different vaccine platforms: live attenuated tetravalent vaccines, intertypic chimeric vaccines (dengue virus vectors and Yellow Fever 17D vector), and recombinant vaccines (flavivirus and non-flavivirus vectors).
• Examination of ongoing human and animal trials for candidate vaccines.

Main Results:

• Several vaccine candidates, including tetravalent live attenuated, intertypic chimeric, and chimeric vaccines, are undergoing human trials.
• Recombinant DNA vaccines utilizing flavivirus and non-flavivirus vectors are in animal trials.
• Emerging data suggests that current tetravalent formulations may induce an imbalanced immune response.

Conclusions:

• Vaccination remains the most promising strategy for dengue prevention due to the lack of effective antiviral drugs and challenges in vector control.
• Ongoing research focuses on optimizing tetravalent vaccine formulations to ensure a balanced immune response against all dengue serotypes.
• Continued development of diverse vaccine platforms is essential to combat the global dengue burden.